Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia

Y. Okahisa, M. Kodama, M. Takaki, T. Inada, N. Uchimura, M. Yamada, Nakao Iwata, M. Iyo, I. Sora, N. Ozaki, H. Ujike

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2 is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and methamphetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous polymorphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomorphism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced psychosis, at least in a Japanese population.

Original languageEnglish
Pages (from-to)190-194
Number of pages5
JournalCurrent Neuropharmacology
Volume9
Issue number1
DOIs
Publication statusPublished - 30-03-2011

Fingerprint

GTP-Binding Protein Regulators
Methamphetamine
Schizophrenia
Genes
Psychotic Disorders
Heterotrimeric GTP-Binding Proteins
Population
Dopamine
Phenotype

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Okahisa, Y. ; Kodama, M. ; Takaki, M. ; Inada, T. ; Uchimura, N. ; Yamada, M. ; Iwata, Nakao ; Iyo, M. ; Sora, I. ; Ozaki, N. ; Ujike, H. / Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia. In: Current Neuropharmacology. 2011 ; Vol. 9, No. 1. pp. 190-194.
@article{63f9ae2317034c7399a60e0936eeb456,
title = "Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia",
abstract = "The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2 is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and methamphetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous polymorphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomorphism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced psychosis, at least in a Japanese population.",
author = "Y. Okahisa and M. Kodama and M. Takaki and T. Inada and N. Uchimura and M. Yamada and Nakao Iwata and M. Iyo and I. Sora and N. Ozaki and H. Ujike",
year = "2011",
month = "3",
day = "30",
doi = "10.2174/157015911795017029",
language = "English",
volume = "9",
pages = "190--194",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Okahisa, Y, Kodama, M, Takaki, M, Inada, T, Uchimura, N, Yamada, M, Iwata, N, Iyo, M, Sora, I, Ozaki, N & Ujike, H 2011, 'Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia', Current Neuropharmacology, vol. 9, no. 1, pp. 190-194. https://doi.org/10.2174/157015911795017029

Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia. / Okahisa, Y.; Kodama, M.; Takaki, M.; Inada, T.; Uchimura, N.; Yamada, M.; Iwata, Nakao; Iyo, M.; Sora, I.; Ozaki, N.; Ujike, H.

In: Current Neuropharmacology, Vol. 9, No. 1, 30.03.2011, p. 190-194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between the regulator of G-protein signaling 9 gene and patients with methamphetamine use disorder and schizophrenia

AU - Okahisa, Y.

AU - Kodama, M.

AU - Takaki, M.

AU - Inada, T.

AU - Uchimura, N.

AU - Yamada, M.

AU - Iwata, Nakao

AU - Iyo, M.

AU - Sora, I.

AU - Ozaki, N.

AU - Ujike, H.

PY - 2011/3/30

Y1 - 2011/3/30

N2 - The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2 is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and methamphetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous polymorphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomorphism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced psychosis, at least in a Japanese population.

AB - The regulator of G-protein signaling (RGS) modulates the functioning of heterotrimeric G protein. RGS9-2 is highly expressed in the striatum and plays a role in modulating dopaminergic receptor-mediated signaling cascades. Previous studies suggested that the RGS9 gene might contribute to the susceptibility to psychotic diseases. Therefore, we investigated the association between the RGS9 gene and two related dopamine psychoses, schizophrenia and methamphetamine use disorders. The subjects comprised 487 patients of schizophrenia and 464 age- and sex-matched healthy controls and 220 patients of methamphetamine use disorder and 289 controls. We genotyped two nonsynonymous polymorphisms, rs12452285 (Leu225Ser) and rs34797451 (His498Arg), of the RGS9 gene. Rs34797451 showed monomorphism in the present Japanese population, but rs12452285 showed polymorphism. There were no significant differences in genotypic or allelic distributions of rs12452285 between patients with schizophrenia and the corresponding control or between patients with methamphetamine use disorder and the corresponding control. We also analyzed the clinical features of methamphetamine use disorder. We found a significant association in allelic distribution with the phenotypes of age at first consumption (p=0.047). The present study suggested that the RGS9 gene is unlikely to play a major role in schizophrenia and methamphetamine dependence liability and/or the development of methamphetamine induced psychosis, at least in a Japanese population.

UR - http://www.scopus.com/inward/record.url?scp=79953056007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953056007&partnerID=8YFLogxK

U2 - 10.2174/157015911795017029

DO - 10.2174/157015911795017029

M3 - Article

VL - 9

SP - 190

EP - 194

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 1

ER -